Cancer drug toxicity: Moving from patient to survivor

Megan Slocum, Sophie F. Garcia, June M. McKoy*

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapter

2 Scopus citations


Millions of individuals worldwide are living with cancer and have remained disease-free for more than 5 years. These individuals are considered to be cancer survivors. The advent of new targeted therapies and personalized treatment modalities have contributed to this increased survivorship. Additionally, earlier diagnosis and detection of cancer, greater access to preventive screenings, and greater focus on cancer pharmaceutical safety have all been contributed to increasing longevity. Of note, all cancer types have benefited in the survivorship arena. The advent of expansive survivorship care planning mandated by national governmental agencies and the emergence of newer classes of drug therapies for cancer are expected to buttress and support cancer survivorship in the coming decades.

Original languageEnglish (US)
Title of host publicationCancer Treatment and Research
PublisherSpringer International Publishing
Number of pages12
StatePublished - Jan 1 2019

Publication series

NameCancer Treatment and Research
ISSN (Print)0927-3042


  • Cancer
  • Drug policy
  • Pharmaceutical safety
  • Survivorship

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Cancer drug toxicity: Moving from patient to survivor'. Together they form a unique fingerprint.

Cite this